Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 14.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | orm 10-K for the year ended December 31, 2024. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 07.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 02.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
| 24.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 01.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 01.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
| 05.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
Stammdaten
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Unternehmen & Branche
| Name | DYNAVAX TECHNOLOGIES CORP |
|---|---|
| Ticker | DVAX |
| CIK | 0001029142 |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 1,82 Mrd. USD |
| Beta | 0,93 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 94,876,000 | 26,927,000 | 0.21 | 946,506,000 | 534,138,000 |
| 2025-06-30 | 10-Q | 95,442,000 | 18,721,000 | 0.14 | 918,449,000 | 494,162,000 |
| 2025-03-31 | 10-Q | 68,164,000 | -96,099,000 | -0.77 | 945,928,000 | 530,941,000 |
| 2024-12-31 | 10-K | 277,246,000 | 27,309,000 | 0.20 | 986,256,000 | 596,799,000 |
| 2024-09-30 | 10-Q | 80,630,000 | 17,594,000 | 0.12 | 1,061,990,000 | 681,427,000 |
| 2024-06-30 | 10-Q | 73,795,000 | 11,386,000 | 0.08 | 1,016,321,000 | 642,849,000 |
| 2024-03-31 | 10-Q | 50,790,000 | -8,721,000 | -0.07 | 986,565,000 | 618,480,000 |
| 2023-12-31 | 10-K | 232,284,000 | -6,389,000 | -0.05 | 997,096,000 | 622,072,000 |
| 2023-09-30 | 10-Q | 69,514,000 | 14,293,000 | 0.10 | 972,933,000 | 604,916,000 |
| 2023-06-30 | 10-Q | 60,249,000 | 3,431,000 | 0.03 | 936,432,000 | 577,205,000 |
| 2023-03-31 | 10-Q | 46,925,000 | -24,332,000 | -0.19 | 969,922,000 | 563,732,000 |
| 2022-12-31 | 10-K | 722,683,000 | 293,156,000 | 1.97 | 985,850,000 | 581,013,000 |
| 2022-09-30 | 10-Q | 167,735,000 | 63,809,000 | 0.43 | 999,337,000 | 500,576,000 |
| 2022-06-30 | 10-Q | 256,464,000 | 128,755,000 | 0.87 | 1,022,999,000 | 422,799,000 |
| 2022-03-31 | 10-Q | 113,992,000 | 32,859,000 | 0.22 | 1,008,975,000 | 287,484,000 |
| 2021-12-31 | 10-K | 439,442,000 | 76,713,000 | 0.57 | 1,039,246,000 | 222,374,000 |
| 2021-09-30 | 10-Q | 108,270,000 | -28,430,000 | -0.24 | 919,711,000 | 67,576,000 |
| 2021-06-30 | 10-Q | 52,767,000 | 4,473,000 | 0.02 | 647,909,000 | 83,380,000 |
| 2021-03-31 | 10-Q | 83,335,000 | 891,000 | 0.01 | 490,119,000 | 99,762,000 |
| 2020-12-31 | 10-K | 46,551,000 | -75,240,000 | -0.78 | 353,272,000 | 58,693,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-15 | Novack David F | Officer, President & COO | Open Market Sale | -114,000 | 15.64 | -1,782,960.00 | -36,2% | |
| 2025-12-24 | Novack David F | Officer, President & COO | Open Market Sale | -30,000 | 15.49 | -464,700.00 | -9,4% | |
| 2025-08-22 | Deep Track Biotechnology Master Fund, Ltd. | 10% Owner | Open Market Sale | -970,143 | 10.59 | -10,273,814.37 | -208,5% | |
| 2025-08-22 | Myers Scott Dunseth | Director | Open Market Purchase | 3,800 | 10.82 | 41,116.00 | +0,8% | |
| 2025-08-21 | Deep Track Biotechnology Master Fund, Ltd. | 10% Owner | Open Market Sale | -1,094,994 | 11.03 | -12,077,783.82 | -245,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.